Physician profile
Angelo Illuzzi
NPI 1598874679
$8,175.50
in general payments reported to CMS, 2019-2025
42 companies · $2,037 in 2025
The $2,037 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $426 · 2021: $690 · 2022: $1,249 · 2023: $1,375 · 2024: $1,723 · 2025: $2,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,013 · Education: $772 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,013.37 |
| Education | $771.84 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,112.00 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $848.40 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $718.01 | 2019-2025 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $669.64 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $658.21 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Harmony Biosciences LLC | $454.18 | 2020-2025 | Wakix |
| Inspire Medical Systems, INC. | $374.71 | 2022-2025 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $318.32 | 2024-2025 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.36 | 2019-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Sanofi-Aventis U.S. LLC | $257.93 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $252.04 | 2019-2024 | Dupixent |
| Philips North America LLC | $246.69 | 2020-2024 | (Ak6) Vest Therapy |
| Resmed Corp | $216.15 | 2024-2025 | |
| Pfizer INC. | $166.34 | 2019-2024 | |
| Grifols USA, LLC | $142.09 | 2019-2025 | Prolastin-C Liquid |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $134.39 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $133.38 | 2019-2023 | Yupelri |
| Axsome Therapeutics, INC. | $121.64 | 2023-2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $116.76 | 2022-2025 | Glassia |
| Amgen INC. | $116.68 | 2022-2025 | Tezspire, Tavneos |
| Janssen Pharmaceuticals, INC | $101.13 | 2019-2022 | |
| Intuitive Surgical, INC. | $100.56 | 2024 | |
| Baxter Healthcare | $87.00 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| United Therapeutics Corporation | $82.70 | 2024-2025 | Tyvaso, Tyvaso |
| Sunovion Pharmaceuticals INC. | $65.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46.05 | 2019 | |
| Zoll Respicardia, INC. | $45.28 | 2024-2025 | Remede System |
| Gilead Sciences, INC. | $37.43 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $31.97 | 2022-2023 | Belsomra |
| Haemonetics Corporation | $30.92 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $25.70 | 2019-2020 | |
| Abbvie INC. | $24.38 | 2024 | |
| Mallinckrodt Hospital Products INC. | $22.23 | 2024 | Acthar |
| Vifor Pharma, INC. | $22.01 | 2025 | Zemaira |
| E.R. Squibb & Sons, L.L.C. | $20.52 | 2022 | |
| Pharming Healthcare, INC. | $19.87 | 2024 | Ruconest |
| Advanced Respiratory, INC | $18.77 | 2019 | |
| Lilly USA, LLC | $17.51 | 2025 | Mounjaro |
| Ani Pharmaceuticals, INC. | $15.65 | 2022 | |
| Verona Pharma, INC. | $15.26 | 2025 | Ohtuvayre |
| Circassia INC. | $13.01 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.87 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Illuzzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.